Company intelligence / Profile preview

Diamante Società Benefit Srl

Verona, Veneto, Italy

Ownership: Private
Development stage: Other

Overview

Diamante is an Italian biotech company developing plant-derived peptide drugs and virus-like nanoparticles to restore self-tolerance in autoimmune diseases. Their lead asset targets Rheumatoid Arthritis with a novel mechanism aiming to avoid broad immunosuppression. Animal studies have shown proof-of-concept efficacy, and the company is preparing for US FDA approval processes.

Therapeutic areas: RheumatologyImmunology
Modalities: Plant-based peptide drugsVirus-like particles displaying immunodominant peptides
Industry: Biotech

Partnerships

Arieli CapitalAngels for WomenFondazione GolinelliItaly-Israel AcceleratorWell4Tech programs with The Bridge Healing Arts Center

Beyond the preview

Go deeper on Diamante Società Benefit Srl.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamante Società Benefit Srl.

Explore the full profile